Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11200639 | 0.91 | ALDH1A1 (0.52) | ALDH1A1MAPTTDP1NPC1RAB9A | |
| SCHEMBL12993689 | 0.88 | MAPT (0.54) | ALDH1A1MAPTGAAMITFPKM | |
| SCHEMBL7121678 | 0.86 | MAPT (0.46) | ALDH1A1MAPTGAAMITFPKM | |
| SCHEMBL823830 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPTPKMHTTNPC1 | |
| SCHEMBL29650091 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTTDP1NPC1RAB9A | |
| SCHEMBL4063903 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTTDP1NPC1RAB9A | |
| SCHEMBL27929922 | 0.83 | PDK1 (0.52) | ALDH1A1MAPTTDP1CYP3A4TSHR | |
| SCHEMBL28218587 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTTDP1NPC1RAB9A | |
| SCHEMBL14798355 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPTTDP1NPC1RAB9A | |
| SCHEMBL377595 | 0.81 | MAPK1 (0.51) | ALDH1A1MAPTPKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230274-B1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20170342034-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342034-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| EP-3230274-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091845-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016091845-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-16 | — | — | WO | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
| EP-0467325-A2 | Carbostyril derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-5082847-A | Antiarrhythmia | SYNTEX (U.S.A.) INC. (US) | 1992-01-21 | — | — | US | disclosed |
| EP-0168729-B1 | CYAN DYE-FORMING COUPLERS AND PHOTOGRAPHIC ELEMENTS AND PROCESSES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-01-04 | — | — | EP | disclosed |
| US-4762925-A | COLOR PHOTOGRAPHY | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-08-09 | — | — | US | disclosed |
| US-4672013-A | 6-HYDROXYL-2H-U,4-BENZOXAZIN-3-(4H)-ONE COUPLER REACTS WITH DEVELOPER TO GIVE INDOANILINE DYE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-06-09 | — | — | US | disclosed |
| US-4591548-A | 6-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1986-05-27 | — | — | US | disclosed |
| EP-0168729-A2 | Cyan dye-forming couplers and photographic elements and processes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1986-01-22 | — | — | EP | disclosed |
| US-3947434-A | 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023539-B2 | Aryl-cyanoguanidine compounds | SMYD2, SETD2, SMYD3 | ALDH1A1 3801/4885MAPT 1747/4885GAA 4312/4885 |
| US-20170342034-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | SMYD2, SETD2, SMYD3 | ALDH1A1 3996/4885MAPT 1402/4885GAA 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.